Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 1,701–1,800 of 2,053
Harada, M., Adam, J., Covic, M., Ge, J., Brandmaier, S., Muschet, C., Huang, J., Han, S., Rommel, M., Rotter, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26027587
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648937
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648910
Bi, J., Zheng, M., Li, K., Sun, S., Zhang, Z., Yan, N., & Li, X. (2024) · Figshare · doi:10.6084/m9.figshare.25608671
Chalmers, E. E. (2025) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.10.002
Shah, V. N., & Akturk, H. K. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408479-references
Aloufi, L. K., Almaysari, R. K., Aljehani, A. T., Almalki Dhaifallah Mohammed, D., & Alnefaie, Z. M. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20254166
Luo, X., Zheng, C., & Wu, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-28010-9
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8270 · Cited by 2
Wulandari, N., Hanifa, R., Balafas, S., Syaripuddin, M., Azam, M., Supardi, S., van der Schans, J., Feenstra, T., & Taxis, K. (2025) · Tropical medicine & international health · doi:10.1111/tmi.70076 · Cited by 3
ADAPTATION OF TEAM-BASED LEARNING METHODS TO CONTEMPORARY PHARMACOLOGY TRAINING OF FUTURE DOCTORS
Lutsenko, О. A. (2025) · The Medical and Ecological Problems · doi:10.31718/mep.2025.29.3.08
Lee, J., Park, S., Kim, E., Park, J.-Y., Rhee, M., Hughes, J. W., Ko, S., Kwon, O., & Lee, E. Y. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e44 · Cited by 2
“7 - 9 Indeed, prescription rates for SGLT2 inhibitors have increased gradually over the past few years.”
DIABETES IN POLAND: EPIDEMIOLOGY, MORTALITY AND DIAGNOSTICS
Koval, I., Romejko, K., Kujawa, B., et al. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4361
Yıldızgören, M. T., Karakaya, İ., Bağcıer, F., & Ucar, C. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251409205
Zheng, Z., Zhang, K., Ma, X., Qian, Y., & Wang, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1723584
Glucose is a ligand-like trigger for secretion of postprandial GLP-1Preprint
Li, C. M., Li, M., Yang, H.-Y., Tian, X., Zhang, C., Zhao, L., Wu, J., Zhang, C., Liu, S., Yang, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.04.697549
Chen, L., Zhang, Q., Duan, B., Wu, X., Wan, H., WEN, B., Han, J., Liu, H., Yang, C., Liu, W., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70420
Yadav, I. K., Tiwari, A., Anas, M., et al. (2025) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3467
Chen, D., & Deng, S. (2026) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2026.103378
“Notably,the superior glycemic outcomes maintained by the Endocrinology department, despite managing complex cases, underscore the value of specialization and expertise in diabetes care (Davies et al., 2022).”
Dinsdale, M. M., Young, K., Cardoso, P., Güdemann, L. M., Jansz, T. T., McGovern, A. P., Jones, A., Pearson, E. R., Hattersley, A. T., McKinley, T. J., et al. (2026) · medRxiv · doi:10.64898/2026.01.07.26343532
Sutrisno, E., Kaniawati, M., Maharani, I., & Sodik, J. J. (2025) · Sciences of Pharmacy · doi:10.58920/sciphar0404502
Liu, J., Yang, Q., Liu, J., & Li, X. (2026) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2026.105345
Dong, R., Gu, L., Li, H., Hu, Y., Liu, H., Kou, X., Zhao, Y., Zhao, M., Shi, B., Hui, G., et al. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s557994
Ray, A., Sreedhara, S. K., Paik, J. M., CROMER, S. J., Bykov, K., Hahn, G., Glynn, R. J., Wexler, D. J., & Patorno, E. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10170-7 · Cited by 2
Takashi, N., Omura, T., Iijima, H., & Ohtera, S. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-111616
Rathi, A., Potale, S., & Rathi, V. (2026) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20260044 · Cited by 1
Lei, Y., Yi, Q., Ji, S., Lu, J., & Yang, Z. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70029
Chang, L., Hassan, S., Chasse, J., Stern, G. M., Gabovitch, D., Zelle, D., Colling, C., Crossen, J., Aronson, S., Oates, M., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107359 · Cited by 1
Parsonage, I., Wainwright, D. W., & Barratt, J. (2026) · BMC Family Practice · doi:10.1186/s12875-026-03185-w · Cited by 1
Navarrete, R. E. T., Fernandes, J., Fonseca, I. M., Silvano, J., Martins, L. S., & Sa, J. R. (2026) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2026.100302
Welters, A., & Lammert, E. (2026) · Springer eBooks · doi:10.1007/978-3-031-96019-2_22
苏, 政. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161335
Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01424-3
Казарян, С. У., Bazarbekovna, B. R., Kassimbekovna, D. A., Р.А., К., Nurlykaimova, Z., Абсатарова, К. С., & Yakubova, M. M. (2026) · Ġylym men densaulyķ saķtau. · doi:10.34689/sh.2025.27.6.019
How to Evaluate and Reduce Micro- and/or Macrovascular Residual Risk?
Hermans, M. P., Lurquin, F. O., Ahn, S. A., Rousseau, M. F., & (R3i), O. B. O. T. R. R. R. I. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_24
Zaveri, K., Kulkarni, G., Nair, R., Shanmugan, G., Dharmadhikari, S. A., Makkar, R. P. S., Jalgaonkar, R., Chatterjee, B. D., Korukonda, K., & Panel, G. I. S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0337107 · Cited by 1
“…recommend incorporating a third agent to reach hemoglobin A1c (HbA1c) targets when dual therapy fails to control blood glucose levels adequately [11]. provided support in the form of salaries for authors GK, RN and KK, but did not have any additional role in the study design, data collection…”
Kwiendacz, H., Cembrowska-Lech, D., Skonieczna‐Żydecka, K., et al. (2026) · medRxiv · doi:10.64898/2026.02.06.26345743
Entzündungskrankheiten: Was leistet eine antientzündliche Ernährung?
Geisler, C., Dörge, M., & Laudes, M. (2026) · Zahnmedizin up2date · doi:10.1055/a-2688-1167
Assa, H. V., Wolf, A., Hilu, R., Giladi, E., Gabarin, M., Losin, I., Arnson, Y., Pereg, D., Assali, A., & Arow, Z. (2026) · Biomedicines · doi:10.3390/biomedicines14020404 · Cited by 1
“…Association and the European Association for the Study of Diabetes also emphasize that women are underrepresented in cardiovascular outcome trials and receive less intensive management of cardiovascular risk factors, despite similar or greater benefit from these therapies compared to men [12].”
Thewjitcharoen, Y., Chatchomchuan, W., Wanothayaroj, E., Butadej, S., Nakasatien, S., & Himathongkam, T. (2026) · Vascular Health and Risk Management · doi:10.2147/vhrm.s582744 · Cited by 3
“35 Our present data also showed the same findings that calcium score of zero was found in more than one-fifth of patients with DM duration ≥20 years.”
Informed Bayesian Models Enhance Personalized Lifestyle Advice for People with Type 2 Diabetes
Snel, T., Krone, T., Pijl, H., et al. (2026) · Diabetes Technology and Obesity Medicine · doi:10.1177/29986702261419479
Erande, S. G., Raykantiwar, A., Samadhan, S. V., Rashmi, G. R., Maiti, A., Kartheek, A. S. V., Hanifah, M., Giri, R., GADVE, S. S., Ray, A., et al. (2026) · Cureus · doi:10.7759/cureus.103676
“Metformin monotherapy is often inadequate for maintaining glucose levels within the target range [5].”
Cao, X., Li, X., Yu, H., Liu, Z., Zhou, F. L., Chen, Z., Shao, W., Zhao, Y., Yang, X., & Li, P. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113166
Khan, H., Ali, K., Fahim, T., Kohli, S., Ali, Z. A., Ali, E. Y., Alshahrani, M. S., Elrefaey, B. H., Mansuri, N., & Ahmad, I. (2026) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2026.103333 · Cited by 1
Wziątek-Kuczmik, D., Mrowiec, A., Stanek, A., et al. (2026) · Archives of Medical Science · doi:10.5114/aoms/218009
“Effective care demands a multidisciplinary, informed, and organized approach, with active patient engagement in self-care [15, 16].”
Martínez-Pérez, Ó., Lorenzo‐Herrero, S., Amado, E., Peralta, F. G., Filgueiras, J. B., Barrot, J., Cordero, A., Crespo, C., Pascual, V., & Cerezales, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041628
“Weight loss is seen as a critical strategy to improve T2D complications, with 5–15% weight loss established as a primary target [8].”
Stump, K., Centeno, D., Talsania, A. J., Morar, H., & Wiekrykas, B. D. (2026) · Hand · doi:10.1177/15589447261422503 · Cited by 1
Korbela, J., & Białek, A. (2026) · Nutrients · doi:10.3390/nu18050742
Gourdy, P., Cazals, L., Lepage, B., FRANÇOIS-MARSAL, C., Schiavi, T., Sieber, J., Flacke, F., & Isz, S. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261417645 · Cited by 2
Weng, Y., Xu, X., 阮敏芝, Zhu, L., Jing, Z., Jin, X., Fengyang, J., & Wang, H. (2026) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2026.112612
Chawla, M. S., Viswanathan, V., Agarwal, S., Maheshwari, A., Sahay, R. K., Jethwani, P., Ghosh, S. K., Gupta, S., Kanodia, N., Unnikrishnan, A. G., et al. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01634-x · Cited by 1
“International and national guidelines (RSSDI) offer adaptable strategies for patient-specific care, emphasizing safe drug choices, appropriate blood glucose (BG) monitoring, dosage adjustments, and nutritional considerations [25–28].”
Wu, Q., Yang, K., Liao, X., Zheng, S., Zheng, X., Wang, H., Yang, J., & Hong, T. (2026) · Biomedicines · doi:10.3390/biomedicines14030572
“In T2DM patients with atherosclerotic cardiovascular disease or high cardiovascular risk, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as an important option [5].”
Íñiguez-Gutiérrez, L., Díaz-Villavicencio, B., Íñiguez-Mosqueda, O., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01903-w
“The primary objectives of medical and nutritional treatment in patients with diabetes are to maintain control of blood glucose, blood pressure, and lipids in the blood and tissues, thereby preventing complications in other organs [8].”
Perspective Chapter: A Critical Overview of Metformin Use from Past to Present
Türk, A. H., & Kılıç, H. C. (2026) · Pharmaceutical science. · doi:10.5772/intechopen.1012223
Identifying high-risk combinations of metformin during COVID-19
Dimnjaković, J., Buble, T., Poljičanin, T., Brborović, H., Brađašević, E., & Brborović, O. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343979
“Metformin typically lowers HbA1c% by about 0.9 percentage points, is weight-neutral or modestly weight-reducing and does not cause hypoglycemia [34,37,38].”
InfluentialSaldívar-Cerón, H. I. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94010021
Li, F., Jiang, Z., Chaveerach, A., Konkobo, F. A., Ansari, M. K. A., Ban, G. F., Konaré, M. A., Manjang, L., Rochelin, Z., Yang, Y., et al. (2026) · Frontiers in Plant Science · doi:10.3389/fpls.2026.1774981 · Cited by 1
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01446-x
Lifestyle Interventions for the Prevention of Type 2 Diabetes Mellitus
Henson, J. J., Davies, M. J., Greaves, C., Khunti, K., & Yates, T. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00003-3
Self-citationBerg, D. D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00008-2
Innovations in technology and therapeutics for diabetes management in older adults
Mehjabin, S., & Akanda, M. K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44665-8.00016-x
DEEDWANIA, P. C., & Banga, A. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.02.049 · Cited by 1
Oltre i target glicemici: effetto legacy e variabilità glicemica nelle complicanze del diabete
Barone, S., & Sacchetta, L. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01765-7
Garg, S., Araujo‐Duran, J., Valencia, S. O., Chatterjee, A., & Lembo, A. J. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251408393
Perelman, M. G., Brzezinski, R. Y., Banai, S., Wolf, I., & Laufer‐Perl, M. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.042404
“25,26 As a result, SGLT2i therapy is now recommended as a class I indication for treating diabetes, HF, and CKD. 27,28 Despite the remarkable clinical outcomes associated with SGLT2i, the underlying mechanisms remain unclear, thought to stem from a combination of improved myocardial energetics,…”
Hoog, M. M., Minghetti, A., & Valentine, W. J. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01846-8 · Cited by 1
“This challenge persists even within the framework of contemporary, patient-centered treatment approaches, highlighting the need for more proactive and timely intervention strategies in the management of type 2 diabetes [11, 12].”
InfluentialTirzepatide and semaglutide: different twins?
Cesaro, A., Acerbo, V., & Calabrò, P. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag028
“9,10 In this context, the therapeutic priority is not merely glycaemic control but cardiovascular prevention, and the choice of GLP-1RA is guided by an organ-protective strategy rather than glucose-lowering alone.”
Wang, L., Wang, Y., & Zhao, Q. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04015-9
Doležal, T., Lamblová, K., Chadimová, K., Decker, B., Kubešová, B., Piljarová, I., Koubková, K., Kostern, M., & Halas, A. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.092
Žďarská, D. J., Raj, P., Kapur, R., Schroner, Z., & Bém, R. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.053
Singh, S., Kumar, R., Maharshi, V., Sinha, N., & Payra, S. (2026) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_357_2025
Fuel toxicity-associated spectrum (FTAS): a unifying nomenclature for metabolic disorders
Sureshkumar, P. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00282-8
“This mandates the early consideration of drug classes with proven pleiotropic benefits, namely GLP-1 receptor agonists and SGLT2 inhibitors as foundational therapy, consistent with their evolving first-line role in modern cardiometabolic guidelines [51, 67].”
Research Progress on Frailty in Patients with Diabetes-Related Foot Disease
黄, 诗. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1631072
Lozada, G. A., Chen, R. B., Davoud, S. C., & Lee, G. S. (2026) · Anesthesiology Clinics · doi:10.1016/j.anclin.2026.02.002
Soliman, A., Hamour, B., Hammad, A., Yousry, O., Samy, S., Hussein, A., Elmorsy, S. A., Nabeh, O. A., Elkholy, E. M., & Salam, R. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01880-0 · Cited by 1
Wannachalee, T., Anthanont, P., Sirisreetreerux, S., Nayak, G., Chumchujan, W., Iamsudjai, Y., & Buranapin, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70701
Mori, T., Kuß, O., Mader, J. K., Naudorf, M., Seufert, J., Holl, R. W., Lanzinger, S., & Grimsmann, J. M. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2798-6496 · Cited by 1
“Third, instead of analyzing glycemic outcomes, we focused on the prevention of cardio-vascular outcomes, for which GLP-1-RA and SGLT2i are major components of current guidelines [1, 5].”
InfluentialCraemer, M. D., Kinaupenne, M., Decraene, M., Bogaert, L., & Willems, I. (2026) · medRxiv · doi:10.64898/2026.03.24.26349179 · Cited by 1
Intoxication par la metformine
Cohen, S., & Vassal, O. (2026) · EMC - Biologie Médicale · doi:10.1016/s2211-9698(25)47062-9
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B. H., & Guthoff, M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01461-y
Umfassende kardiorenale Protektion durch SGLT2-Hemmer
Rawish, E., & Eitel, I. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02098-1
Management strategies in older adults with diabetes mellitus and polypharmacy; a narrative review
Seyithanoğlu, D., Erdoğan, T., & Bahat, G. (2026) · HORMONES · doi:10.1007/s42000-026-00775-2
Medication Deprescribing Practices Among Lifestyle Medicine Providers: A Cross-Sectional Survey
MacField, J. F., Staffier, K. L., Kelly, J. H., Moghe, R. A., & Karlsen, M. C. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261430281
Chahar, A. S., Chauhan, N., Tiwari, P., Shukla, A., & Sharma, P. (2026) · Cureus · doi:10.7759/cureus.106092
“…Association (ADA), American Association of Clinical Endocrinologists (AACE), and International Diabetes Federation (IDF) advocate the importance of integrating MNT in the management of T2DM as a first-line therapy and provide consistent recommendations for day-to-day nutritional needs [11,12].”
Hypothalamus-liver talks: whispers in the language of metabolism
Ferreira, V., Fernández-González, I., Vattathara, J. J., Rodríguez-Díaz, A., Fernández-Sanmartín, P., & Diéguez, C. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10031-y
“Notably, adiponectin-deficient mice are refractory to gastric emptying, and is strongly recommended in the treat-ment of T2D [152] and obesity [153, 154].”
Zhu, X., Wang, X., Zhang, P., Yang, Z., Zhao, N., Li, J., Shi, Y., Zhao, Y., & Ma, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1750615 · Cited by 1
“This strongly supports the recommendations in the latest clinical guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) organization (49) and the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) (50).”
Guerra, C., Corréard, F., Montégut, C., Nakache, J., Arcani, R., Mascio, T. D., Villani, P., Honoré, S., Daumas, A., Couderc, A., et al. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07410-0
“The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) also recommend a personalized approach [14].”
Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use
Arslanian, S. A., Barrett, T. G., & Shehadeh, N. (2026) · Pediatric Diabetes · doi:10.1155/pedi/4555805
“…treatment guidelines from the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), and International Society for Pediatric and Adolescent Diabetes (ISPAD) recommend metformin as the fi rst-line therapy for the management of youth-onset T2D [24, 40, 41].”
Kaibagarova, I., Ablakimova, N., Smagulova, G., Мавлюдова, Н. М., Mussina, A. Z., Ovsiannikova, A. N., Sartayeva, A., & Zhamaliyeva, L. M. (2026) · Ġylym men densaulyķ saķtau. · doi:10.34689/sh.2026.28.1.006 · Cited by 1
Alba-Linero, C., Ruiz, J. C., Luque, M. M., Espíldora-Hernández, J., & Gutiérrez‐Bedmar, M. (2026) · Diabetology · doi:10.3390/diabetology7040065
The Influence of Polypharmacy on Type 2 Diabetes Adverse Cardiovascular Outcomes in a Rural CohortPreprint
Li, J. W., Crew, L. A., Cox, T. M., et al. (2026) · medRxiv · doi:10.64898/2026.04.02.26350053
“With an increasing list of medications, adherence decreases, leading to suboptimal outcomes and heightened risk for complications, mortality, and hospital admissions 4,5 .”
Kidney Transplant Outcomes in Patients with and without Type II Diabetes Mellitus
Lindeman, J. H. N., Ploeg, R. J., Sharples, E. J., Alwayn, I. P. J., Bemelman, F. J., Berger, S. P., Christiaans, M. H. L., Konijn, C., de Vries, A. P. J., van de Wetering, J., et al. (2026) · Cardiorenal Medicine · doi:10.1159/000551839
Herring, L., Baillot, A., Chaput, J., CHASTIN, S. F. M., Davies, M. J., Dempsey, P. C., Henson, J. J., Papamargaritis, D., Papasavas, P. K., Rowlands, A. V., et al. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.03.022
Self-citationAbdelMagid, A. M., Kamel, A. M., & Farid, S. F. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70142
Evert, A. B. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0002
New generation anti-obesity drugs and bone health in postmenopausal women
Studýnková, J. T. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.022
Dong, C.-F., He, F., & Guo-Bin, K. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i4.115721
Kwiendacz, H., Cembrowska-Lech, D., Skonieczna‐Żydecka, K., Klimontowicz, K., Podsiadło, K., Wierzbicka-Woś, A., Styburski, D., Kaczmarczyk, M., Gumprecht, J., Łoniewski, I., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119370 · Cited by 1
Jurin, I., Gjuras, K., Bešić, D., Jurin, H., Kursar, J., Cvetko, T.-T., Rode, F., Šipić, T., Lišnjić, P., Manola, Š., et al. (2026) · Cardiology · doi:10.1159/000551964
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.